{"id":"NCT01650246","sponsor":"Ardea Biosciences, Inc.","briefTitle":"Open-Label Lesinurad Monotherapy Extension Study in Gout","officialTitle":"A Long-Term Open-Label Extension Study for Subjects Completing a Phase 3 Efficacy and Safety Study of Lesinurad Monotherapy in Subjects With Gout","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-08","primaryCompletion":"2014-04","completion":"2014-08","firstPosted":"2012-07-26","resultsPosted":"2016-05-26","lastUpdate":"2016-05-26"},"enrollment":143,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Gout"],"interventions":[{"type":"DRUG","name":"lesinurad","otherNames":[]}],"arms":[{"label":"lesinurad 400 mg","type":"EXPERIMENTAL"}],"summary":"This study will assess the serum uric acid lowering effects and safety of lesinurad over a long-term timeframe.","primaryOutcome":{"measure":"Proportion of Subjects With a Serum Urate (sUA) Level That is < 6.0 mg/dL","timeFrame":"Month 1","effectByArm":[{"arm":"Lesinurad 400 mg","deltaMin":68,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":3},"locations":{"siteCount":75,"countries":["United States","Australia","Belgium","Canada","Germany","New Zealand","South Africa"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":15,"n":143},"commonTop":["Blood creatinine increased","Upper respiratory tract infection","Hypertension","Gastroenteritis","Urinary tract infection"]}}